Here we used the mitogen-activated protein kinase (MAPK) pathway inhibitors vemurafenib (PLX4032) (mutant BRAF inhibitor, mBRAFi) and trametinib (MEK inhibitor, MEKi) as these are frontline therapeutics in the management of melanoma in the clinic. Here, MAP2K7 is linked to melanoma.